Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN

Mayo Clinic has licensed patent rights from QIAGEN to enable Mayo Medical Laboratories to offer an M. tuberculosis complex speciation test. The test expands Mayo Medical Laboratories' current offering for tuberculosis testing, which already includes M. tuberculosis complex culture, molecular identification and drug susceptibility testing. In addition, Mayo Medical Laboratories offers polymerase chain reaction (PCR) detection of M. tuberculosis complex directly from specimens and molecular detection of drug resistance markers for the drugs isoniazid and pyrazinamide.

Tuberculosis (TB) is a disease caused by M. tuberculosis complex. The bacteria usually attack the lungs, but also can attack other parts of the body such as the kidney, spine and brain. If not treated properly, TB disease can be fatal. Tuberculosis once was the leading cause of death in the United States. If left untreated, it can kill over 50 percent of its victims.

Mayo Medical Laboratories routinely identifies M. tuberculosis complex in the laboratory using Food and Drug Administration (FDA)-approved nucleic acid hybridization probes. This approach is appropriate when the physician wants to confirm that the patient is infected with M. tuberculosis complex but cannot tell the physician if the culprit is the species M. tuberculosis or another species member of the complex, such as M. bovis, M. bovis BCG and M. africanum.

"When the clinical history of a patient suggests that it might be one of these other members of the complex, the physician will ask for speciation to know which species, usually M. tuberculosis, M. bovis, or M. bovis BCG, is causing the patient's disease. The treatment plan and the public health contact investigation associated with TB disease may differ depending on which species has been identified," explains Nancy Wengenack, Ph.D., director of the Mycobacteriology Laboratory, Mayo Clinic Department of Laboratory Medicine and Pathology.

Source:

Mayo Medical Laboratories/Department of Laboratory Medicine and Pathology

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Qiagen. (2019, June 17). Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN. News-Medical. Retrieved on August 02, 2021 from https://www.news-medical.net/news/20110719/Mayo-Clinic-licenses-M-tuberculosis-complex-speciation-test-from-QIAGEN.aspx.

  • MLA

    Qiagen. "Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN". News-Medical. 02 August 2021. <https://www.news-medical.net/news/20110719/Mayo-Clinic-licenses-M-tuberculosis-complex-speciation-test-from-QIAGEN.aspx>.

  • Chicago

    Qiagen. "Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN". News-Medical. https://www.news-medical.net/news/20110719/Mayo-Clinic-licenses-M-tuberculosis-complex-speciation-test-from-QIAGEN.aspx. (accessed August 02, 2021).

  • Harvard

    Qiagen. 2019. Mayo Clinic licenses M. tuberculosis complex speciation test from QIAGEN. News-Medical, viewed 02 August 2021, https://www.news-medical.net/news/20110719/Mayo-Clinic-licenses-M-tuberculosis-complex-speciation-test-from-QIAGEN.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
FDA approves QIAGEN’s therascreen EGFR test as companion diagnostic for NSCLC patients